Two Sigma Advisers LP Has $894,000 Stake in Allscripts (MDRX)

Two Sigma Advisers LP reduced its stake in Allscripts (NASDAQ:MDRX) by 86.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 61,413 shares of the software maker’s stock after selling 406,003 shares during the period. Two Sigma Advisers LP’s holdings in Allscripts were worth $894,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Neuberger Berman Group LLC raised its stake in shares of Allscripts by 5.5% in the third quarter. Neuberger Berman Group LLC now owns 3,676,088 shares of the software maker’s stock valued at $52,311,000 after acquiring an additional 190,158 shares in the last quarter. Dalton Greiner Hartman Maher & Co. raised its stake in shares of Allscripts by 18.4% in the fourth quarter. Dalton Greiner Hartman Maher & Co. now owns 2,990,902 shares of the software maker’s stock valued at $43,518,000 after acquiring an additional 465,037 shares in the last quarter. Fisher Asset Management LLC raised its stake in shares of Allscripts by 1.8% in the fourth quarter. Fisher Asset Management LLC now owns 2,386,237 shares of the software maker’s stock valued at $34,720,000 after acquiring an additional 42,504 shares in the last quarter. Systematic Financial Management LP raised its stake in shares of Allscripts by 14.3% in the fourth quarter. Systematic Financial Management LP now owns 2,118,015 shares of the software maker’s stock valued at $30,817,000 after acquiring an additional 264,715 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Allscripts by 18.2% in the fourth quarter. Geode Capital Management LLC now owns 1,913,696 shares of the software maker’s stock valued at $27,844,000 after acquiring an additional 294,993 shares in the last quarter.

How to Become a New Pot Stock Millionaire

MDRX opened at $12.02 on Monday. The company has a debt-to-equity ratio of 1.33, a quick ratio of 0.97 and a current ratio of 0.97. Allscripts has a one year low of $10.78 and a one year high of $16.13. The stock has a market cap of $2,144.33, a PE ratio of 25.57, a PEG ratio of 1.55 and a beta of 1.23.

Allscripts (NASDAQ:MDRX) last posted its earnings results on Thursday, February 15th. The software maker reported $0.18 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.18. Allscripts had a positive return on equity of 7.36% and a negative net margin of 10.88%. The business had revenue of $547.00 million for the quarter, compared to analysts’ expectations of $524.05 million. During the same quarter in the previous year, the firm earned $0.14 earnings per share. The business’s revenue was up 27.5% compared to the same quarter last year. equities research analysts anticipate that Allscripts will post 0.56 EPS for the current year.

In other news, EVP Brian Farley sold 5,000 shares of Allscripts stock in a transaction dated Wednesday, March 14th. The stock was sold at an average price of $13.73, for a total transaction of $68,650.00. Following the sale, the executive vice president now owns 240,672 shares in the company, valued at $3,304,426.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Richard J. Poulton sold 15,000 shares of Allscripts stock in a transaction dated Thursday, March 15th. The stock was sold at an average price of $13.53, for a total value of $202,950.00. Following the sale, the president now owns 505,920 shares in the company, valued at approximately $6,845,097.60. The disclosure for this sale can be found here. 0.75% of the stock is currently owned by insiders.

Several analysts have recently issued reports on the company. Zacks Investment Research upgraded Allscripts from a “sell” rating to a “hold” rating in a research note on Thursday, January 25th. ValuEngine cut Allscripts from a “hold” rating to a “sell” rating in a research note on Tuesday, April 3rd. BidaskClub cut Allscripts from a “hold” rating to a “sell” rating in a research note on Wednesday, April 4th. Cantor Fitzgerald restated a “buy” rating and issued a $17.00 price target on shares of Allscripts in a research note on Sunday, January 28th. Finally, Citigroup began coverage on Allscripts in a research note on Thursday, January 4th. They issued a “buy” rating on the stock. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and eleven have given a buy rating to the company’s stock. Allscripts presently has an average rating of “Hold” and a consensus target price of $16.22.

COPYRIGHT VIOLATION WARNING: “Two Sigma Advisers LP Has $894,000 Stake in Allscripts (MDRX)” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/16/two-sigma-advisers-lp-has-894000-stake-in-allscripts-mdrx.html.

Allscripts Profile

Allscripts Healthcare Solutions, Inc provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records, connectivity, private cloud hosting, outsourcing, analytics, patient engagement, clinical decision support, and population health management solutions.

Want to see what other hedge funds are holding MDRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allscripts (NASDAQ:MDRX).

Institutional Ownership by Quarter for Allscripts (NASDAQ:MDRX)

Receive News & Ratings for Allscripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply